

Formulation and Evaluation of Matrix Tablet of Mesalazine with Hydroxypropylmethylcellulose Phthalate

Lone Krishnakumar Devrao^{1*} Dhole Jyoti Arjunrao² and Dhole Nagesh Arjunrao³

^{1*}JSPM's Rajarshi Shahu College of Pharmacy and Research, Tathawade, Pune, Maharashtra, India.

²Department of Botany, Yeshwant Mahavidyalaya, Nanded, Maharashtra, India.

³School of Life Sciences, S.R.T.M. University, Nanded, Maharashtra, India.

ABSTRACT

Mesalazine is considered as a gold standard anti-inflammatory agent for treatment of inflammatory bowel diseases. It is mostly utilized for treatment and maintenance of remission in mild to moderate Ulcerative colitis. Orally ingested Mesalazine is efficiently absorbed by small bowel and rapidly clear from circulation, with elimination half life of only 1 hour. Therapeutic concentration in colon can be achieved by oral ingestion of delayed or slow released matrix preparations. In the present study slow released matrix tablets of Mesalazine were prepared using pH sensitive polymer HPMC-P with six concentrations by wet granulation method. The granules were evaluated for angle of repose, bulk density, tapped density, compressibility index and Hausners ratio. The tablets were subjected to weight variation, hardness, friability and drug content test. Invitro release studies revealed that only one formulation, P3 qualified the first stage of release while all the formulations qualified the second stage of drug release except P4 which deviated slightly. The release profiles were affected by variable concentration of matrix forming polymer and hence, the release of Mesalazine retarded with increase in proportion of HPMC-P. As HPMC-P is a pH sensitive polymer with threshold value 5.8 because of this effectively prevented the escape of drug at acid stage but allowed considerable amounts to be released in buffer stage I.

Keywords: Mesalazine, HPMC-P, Ulcerative colitis, wet granulation.

INTRODUCTION

Colonic drug delivery has gained increased importance not just for the delivery of drugs for the treatment of local diseases of colon such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis (UC) but also for its potential for the delivery of proteins and therapeutic peptides like insulin. (Swarbrick et al., 1991; Basti A.W., 2005) Ulcerative colitis is a chronic inflammation of the large intestine (colon). It is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. Ulcers are formed at sites where inflammation has killed the cells that usually line the colon, which then bleed and produce pus. It is closely related to another condition of inflammation of the intestine called

Crohn's disease. Together, they are frequently referred to as inflammatory bowel diseases (IBD). (Rembacken et al., 1999)

Mesalazine is used as anti-inflammatory agent for treatment of inflammatory bowel diseases. It is mostly utilized for treatment and maintenance of remission in mild to moderate Ulcerative colitis. Orally ingested Mesalazine is efficiently absorbed by small bowel and rapidly clear from circulation, with elimination half life of only 1 hour. (Bruce L.D., 2005) Therapeutic concentration in colon can be achieved by oral ingestion of delayed or slow released matrix preparations. The delayed released matrix tablets were formulated to minimize escape of drug mesalazine in upper part of GIT and provide maximum amount to the colon. As HPMC-P is a pH sensitive polymer with

threshold value 5.8 because of which it could effectively prevent the escape of drug at acid stage but allowed considerable amounts to be released in buffer stage I. (Orlu, 2006).

MATERIALS AND METHODS

Materials

Mesalazine was Kind gift from Sarex pharma Mumbai India. HPMC-P kindly supplied by Ideal Cures Pvt. Ltd Thane, Povidone (PVP-K30) & microcrystalline cellulose gifted by Signet chemical corporation, Mumbai. Talc and Magnesium stearate were procured from

Emcure House M.I.D.C. Pune. All other chemicals and reagents used were of analytical grade.

Preparation of Mesalazine S.R. matrix tablets

For preparing matrix tablets the content of Mesalazine was maintained at 250 mg in each type of formulation. The accurately weighed quantities of selected polymers and drug were mixed in various proportions and mixtures were assigned different formulation codes presented in table-1 (Aulton, 1998).

Table 1: Formulations of the matrix tablets of Mesalazine

S. No.	INGREDIENTS (%W/W)	Formulation codes					
		P1	P2	P3	P4	P5	P6
1	Mesalazine	50	50	50	50	50	50
2	HPMC-P 55S	15	15	25	25	35	35
3	PVP K-30	3	5	3	5	3	5
4	Magnesium state	1	1	1	1	1	1
5	Aerosil	1	1	1	1	1	1
6	Talc	30	28	20	18	10	8

Weight of one tablet is 500mg

The active ingredients Mesalazine, the polymers, Hydroxypropylmethylcellulose Phthalate were passed through screen (60 #). The physical mixtures of drug, polymers and excipients were prepared by blending the accurately weighed quantities of each of them with Mesalazine in geometric proportions in glass mortar for 15 minutes. Ethnolic solutions of PVP K-30 (3% w/v and 5% w/v) were used as binders which were added gradually to powder blends with trituration until a coherent moist mass was formed. This mass was passed through screen (22#) to get moderately coarse granules. The wet granules were dried at 50°C for 1 hour. The dried granules were again passed through screen (44#) to obtain fine granules. The resulting granules were lubricated with magnesium stearate and then evaluated for following flow properties bulk density, tapped density, compressibility index (C.I.) & Angle of repose (θ).

The granules of each formulation type were compressed into matrix tablets using S.S. punches (diameter 13 mm flat surface) on rotary tablet press. The

compression force was maintained in such a way that the hardness of resulting tablets ranged between 7-8 Kg / m². The batch size prepared for each formulations was of 25 tablets.

Evaluation of matrix tablets of Mesalazine

➤ Weight variation

This test was performed as per procedure described in Indian Pharmacopoeia (1996) using 10 tablets of each formulation type. The tablets were weighed individually and their mean weight was calculated. The deviation of individual weight from the mean was expressed as standard deviation. The compliance of tablets with recommended allowances for variations in weight was judged on the basis of official specifications.

➤ Hardness

Hardness of three tablets of each formulation type was determined using Monsanto hardness tester following the procedure described in standard text book (Lieberman, 2001).

➤ Friability

The friability of 10 tablets of each formulation type was noted using Roche friabilator following the procedure described in standard text book (Lieberman, 2001,). And the weight loss (% w/w) was calculated using following formula,

$$\% \text{ Friability} = (\text{Loss in weight/ Initial weight}) \times 100$$

➤ Drug contents

The contents of Mesalazine were estimated using 5 tablets of individual formulations. The tablets were weighed individually, and were crushed in mortar. From this, the powder equivalent to 250 mg of Mesalazine was taken in volumetric flasks and dissolved in sufficient quantity of phosphate buffer (pH 7.2) and the final

volume was made up to 100 ml. Appropriate dilutions of the resulting solutions were carried out and the contents of Mesalazine were estimated from UV absorbance of these solutions at 331 nm using previously prepared calibration curve of Mesalazine in phosphate buffer pH 7.2 (Acarturk 2007).

➤ *In vitro* release of Mesalazine from matrix tablets

The test was conducted using three matrix tablets of each type of formulation using USP (23) dissolution apparatus (Apparatus I). The tablets of each type of matrix formulations were kept in baskets which were placed successively in below mentioned dissolution media. The dissolution apparatus was run maintaining below stated test conditions represented in table-2.

Table 2: The experimental conditions used for *in vitro* release of Mesalazine from matrix tablets

Phases	Type and volume of dissolution medium	Speed of rotation (rpm)	Duration (min)	λ max used for recording absorbance	Volume withdrawn & frequency of withdrawn of aliquots
Phase I Acid stage	0.1N HCl 500ml pH- 3	100 rpm	120	303.0	10ml at intervals of 30min
Phase II Buffer stage-1	phosphate buffer 900ml pH- 6	100 rpm	60	330.0	10ml at intervals of 30min
Phase III Buffer stage-2	phosphate buffer 900ml pH-7.2	50 rpm	90	331.0	10ml at intervals of 30min

➤ Stability Studies

Stability studies were carried out to assess the stability of all formulated sustain release Mesalazine tablets (Bruce LD, et al). The prepared tablets were kept at $45^{\circ} \pm 2^{\circ} \text{C}$, $75 \pm 5\%$ RH for 45 days. At 15 days intervals the tablets were evaluated for all physical parameters. The percentage of Mesalazine content and *In vitro* drug release studies were also determined.

RESULTS AND DISCUSSION

Evaluation of Mesalazine Granules

The values for loose bulk density, tapped bulk density, compressibility index and angle of repose of granules of Mesalazine

prepared with HPMC-P, revealed different behavior of each formulation blend expressed in table-3. Thus, the values for granules of Mesalazine with HPMC-P are more consistent. However, all these values are still suggestive of good flowability of blends.

Values of loose bulk density and tapped bulk densities for Mesalazine granules ranged between HPMC P: 0.416-0.482 and 0.531-0.552 gm/ml. The Carr's index values ranged between 10.16-22.67, the values of angle of repose 25.33-27.25. All the flow characteristics are satisfactory for subsequent processing of granules for preparation of matrix tablets of Mesalazine.

Table 3: Flow properties of granules of Mesalazine with individual pH sensitive HPMC polymers and their combination with sodium alginate

Code	Loose bulk density (g/ml)	Tapped bulk density (g/ml)	Carr's Compressibility Index. (%)	Angle of repose(θ)
P1	0.471 \pm 0.0174	0.534 \pm 0.004	11.79 \pm 0.012	27.14 \pm 0.022
P2	0.467 \pm 0.0184	0.543 \pm 0.005	13.99 \pm 0.022	26.80 \pm 0.019
P3	0.482 \pm 0.0193	0.552 \pm 0.004	12.68 \pm 0.022	25.33 \pm 0.017
P4	0.477 \pm 0.0190	0.531 \pm 0.011	10.16 \pm 0.021	27.25 \pm 0.014
P5	0.416 \pm 0.0195	0.538 \pm 0.005	22.67 \pm 0.011	25.97 \pm 0.014
P6	0.468 \pm 0.0189	0.549 \pm 0.004	14.75 \pm 0.020	26.20 \pm 0.013

All values are expressed as mean \pm SD, n=3

Evaluation of Mesalazine Tablets

The matrix tablets of Mesalazine prepared with HPMC-P were characterized for various tablet characteristics as per the monograph mentioned in table-4.

The pharmacopoeial specifications for deviation in weight from average weight for tablets weighing more than 250 mg are \pm 5%. The percentage deviation in the weight of prepared tablets (weighing 500 mg) was within the specified limits for all the formulation types and hence, they complied with the test for weight variation. Diameter of the matrix tablets was in the range of 12.88-12.93mm. Thickness of the matrix tablets was in the range of 3.31-3.37 mm. Hardness of matrix tablets was in the range of 8-9 Kg/cm², Friability of the

matrix tablets of Mesalazine with 0.30-0.41 %.

The matrix tablets of different formulations possessed consistent dimensions and hardness values and all of them complied with the specified limits for friability (<1%). The higher values of hardness may be justified since drug is targeted for colon and the inclusion of pH sensitive polymer would ensure its release in the destined organ. The pharmacopoeial specifications for permissible allowances for deviation in % drug contents for tablets of Mesalazine is not less than 98% and not more than 101% of the labelled amount. (USPNF 2004). The percent drug contents for Mesalazine formulations with HPMC-P (HF) ranged between 97.42-99.36 Hence, the tablets complied with the official specifications.

Table 4: Characterization of matrix tablets of Mesalazine

code	Avg. weight (mg)	Diameter (mm)	Thickness (mm)	Hardness (Kg/cm ²)	Friability (%)	Drug Content (%)
P1	501 \pm 1.02	12.90	3.31	8.0	0.41	97.42 \pm 0.156
P2	499 \pm 0.56	12.93	3.36	8.5	0.30	98.36 \pm 0.145
P3	498 \pm 1.85	12.91	3.37	8.5	0.32	99.25 \pm 0.156
P4	499 \pm 0.35	12.92	3.33	9.0	0.31	98.65 \pm 0.172
P5	501 \pm 1.35	12.88	3.31	8.0	0.36	99.36 \pm 0.198
P6	498 \pm 0.55	12.90	3.35	8.0	0.35	98.54 \pm 0.154

All values are expressed as mean \pm SD, n=3

In vitro release of Mesalazine from matrix tablets

The USP specifications for % cumulative release of drug from colon targeted dosage forms are;

- Acid stage: Not more than 12% of LA.

- Buffer stage 1: Not more than 30% of LA (LA is labelled amount).

In vitro release of Mesalazine from matrix tablets prepared with variable concentration of HPMC-P.

Only one formulation, P3 qualified the first stage of release while all the formulations qualified the second stage of drug release except P4 which deviated slightly.


The release profiles were affected by variable concentrations of matrix forming polymer and hence, the release of Mesalazine retarded with increase in

proportion of HPMCP-55S (Table-5, Fig- 1 a, b, c). HPMC-P is also a pH sensitive polymer with the threshold value of 5.8 because of which it effectively prevented the escape of drug at acid stage but allowed considerable amounts to be released in buffer stage I


Table 5: Dissolution data of matrix tablets of Mesalazine with variable concentration of HPMC-P

Dissolution phase & duration.	Time (min.)	Cumulative (avg.) % drug release					
		HPMCP : PVP K30	HPMCP : PVP K30	HPMCP : PVP K30	HPMCP : PVP K30	HPMCP : PVP K30	HPMCP : PVP K30
		15:3 (%)	15:5 (%)	25:3 (%)	25:5 (%)	35:3 (%)	35:5 (%)
		P1	P2	P3	P4	P5	P6
Acid stage pH= 3 (120 minutes)	0	0	0	0	0	0	0
	30	6.60±1.20	7.75±1.81	6.05±1.17	6.48±1.14	4.93±1.12	5.48±1.10
	60	8.52±0.54	9.83±1.42	8.65±1.15	9.68±1.28	7.45±0.98	6.86±0.44
	90	10.80±0.37	12.43±0.32	10.78±0.42	11.34±0.42	10.65±0.59	11.29±1.21
	120	13.77±0.94	14.21±1.12	12.88±0.22	13.47±0.87	14.69±0.21	13.69±0.36
Buffer stage-1 pH=6 (60 minutes)	150	26.51±1.10	27.65±1.21	28.54±1.13	29.37±0.58	27.14±1.31	26.25±1.20
	180	29.05±0.84	29.64±0.74	30.33±1.42	31.59±1.05	28.01±1.54	27.40±1.27
Buffer stage 2 pH= 7.2 (90 minutes)	210	62.43±1.24	61.83±2.15	64.21±1.34	63.12±1.37	50.47±1.39	48.74±1.12
	240	82.93±2.05	83.27±1.12	76.84±2.13	75.54±1.34	61.43±2.63	59.91±2.56
	270	98.78±2.14	97.53±2.08	90.18±1.26	88.12±2.61	76.19±1.13	78.32±1.42
	300	--	--	100.4±1.21	99.52±1.45	88.44±1.32	91.42±1.21
	330	--	--	--	--	98.62±2.36	99.32±2.17


*The dissolution studies were extended by 60 minutes in buffer stage 2 (pH7.2) for estimating time taken for complete release of drug contents.



(a)



(b)



(c)

Fig. a, b, c: *In vitro* release of Mesalazine from matrix tablets prepared with HPMC-P 55S.

Stability Studies

Mesalazine matrix tablets from all the formulations were stored at $45^{\circ}\pm 2^{\circ}\text{C}$, $75 \pm 5\%$ RH upto 45 days. Tablet evaluation tests were carried out at every 15 days intervals. All the formulations are physically stable. There were no deviations found in the tests and all are within the limits. There were no significant change in the drug content and *In vitro* drug release profiles. It showed that all the formulations are chemically stable.

CONCLUSION

The results of experimental studies of Mesalazine matrix tablets proved that the granules of Mesalazine showed good flow properties, tablet evaluation tests are within the acceptable limits. The dissolution profile indicate that only one formulation S3 able to prevent escape of Mesalazine in acidic pH, of not more than 12% of labeled amount. All other formulations minimize escape of Mesalazine in buffer stage 1 (pH 6) i.e. not

more than 30% of labeled amount, but P4 formulation deviates slightly. HPMC-P tries to offered better protection from escape of Mesalazine in precolonic pH stages. Hence matrix tablets of Mesalazine with optimum concentration of HPMC-P were successfully developed. It was concluded that Mesalazine-HPMC-P matrix tablets can deliver the drug to small and large intestine.

ACKNOWLEDGEMENT

The authors are thankful to Sarex Pharma Pvt Ltd Mumbai, India for providing gift sample of Mesalazine and Ideal Cures Pvt. Ltd Thane, for gift sample HPMC-P 55S. Authors wish to thanks JSPM's Rajarshi Shahu college of Pharmacy & Research, Pune for providing necessary facilities to carry out the work.

REFERENCES

1. Acarturk F, Demiroz FT and Takka S. Evaluation of alginate based mesalazine tablets for intestinal drug delivery. *Eur J Pharm Sci.* 2007;67:491-497.
2. Aulton ME and Wells TI. *Pharmaceutics: The science of dosage form design.* 2nd ed. London, England: Churchill Livingstone, 1998; 208.
3. Basit AW and Wilson PJ. Exploiting gastrointestinal bacteria to target drugs to the colon: An in vitro study using amylase coated tablets. *Int J Pharm.* 2005;300:89-64.
4. Basit AW, Parsons GE, Fadda HM and Ibekwe VC. A comparative in vitro assessment of the drug release performance of pH responsive polymers for ileo-colonic delivery. *Int J Pharm.* 2006;308:53-60.
5. Bruce LD, Shah NH, Malick W and Infed MH. Properties of hot-melt extruded tablet formulation for the colonic delivery of 5 -amino salicylic acid. *Eur J Pharm Sci.* 2005;59:85-97
6. Fassihi RA, McPhillips AM, Uraizee SA and Sakr AM. Potential use of magnesium stearate and talc as dissolution retardants in the development of controlled release drug delivery systems. *Pharm Ind.* 1994;56:579-583.
7. Lachman L, Lieberman HA and Kanig JL. *The theory and practice of industrial pharmacy,* 3rd ed. Bombay: Verghese publishing house. 1990;184.
8. Orlu M, Cevher E and Araman A. Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges. *Int J Pharm.* 2006;318:103-117.
9. *Pharmacopoeia of India,* New Delhi: Ministry of Health and Family Welfare, Government of India, Controller of Publication; 1996.
10. Rembacken BJ, Snelling AM and Hawkey PM. Non pathogenic *Escherichia coli* versus mesalazine for the treatment of ulcerative colitis- randomized trial. *The Lancet.* 1999; 354:635-639.
11. Sadeghi F, Garekani HA and Akhgari A. Combination of time dependent and pH dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets. *Int J Pharm.* 2006;320:137-142.
12. Swarbrick J and Boylan JC. Targeting of drugs to the gut. *Encyclopedia of pharmaceutical technique.* Marcel Dekker, Newyork. 1991;18:287-302.